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Summary
The inactivation of one X chromosome in females is
normally random with regard to which X is inactivated.
However, exclusive or almost-exclusive inactivation of
one X may be observed in association with some X-
autosomal rearrangements, mutations of the XIST gene,
certain X-linked diseases, and MZ twinning. In the pres-
ent study, a methylation difference near a polymorphism
in the X-linked androgen-receptor gene was used to in-
vestigate the possibility that nonrandom X inactivation
is increases in fetuses and newborns that are associated
with confined placental mosaicism (CPM) involving an
autosomal trisomy. Extreme skewing was observed in 7
(58%) of 12 cases with a meiotic origin of the trisomy,
but in none of 10 cases examined with a somatic origin
of the trisomy, and in only 1 (4%) of 27 control adult
females. In addition, an extremely skewed X-inactiva-
tion pattern was observed in 3 of 10 informative cases
of female uniparental disomy (UPD) of chromosome 15.
This may reflect the fact that a proportion of UPD cases
arise by “rescue” of a chromosomally abnormal con-
ceptus and are therefore associated with CPM. A skewed
pattern of X inactivation in CPM cases is hypothesized
to result from a reduction in the size of the early-em-
bryonic cell pool, because of either poor early growth
or subsequent selection against the trisomic cells. Since
∼2% of pregnancies detected by chorionic villus sam-
pling are associated with CPM, this is likely a significant
contributor to both skewed X inactivation observed in
the newborn population and the expression of recessive
X-linked diseases in females.
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Introduction
Dosage compensation in mammals is achieved by the
inactivation of one X chromosome in females during
early embryogenesis (Lyon 1961). Although X inacti-
vation in humans is normally considered to be random
in the embryo proper, primary nonrandom inactivation
can be caused by mutations at the XIST locus (Plenge
et al. 1997), as has also been reported for Xist in mice
(Penny et al. 1996). Secondary nonrandom inactivation
resulting from a selective advantage or disadvantage of
cells may result in nonrandom inactivation in carriers
of X rearrangements or certain X-linked diseases (Mig-
eon et al. 1981; Schmidt and Du Sart 1992). Further-
more, tissue-specific, nonrandom X inactivation may
arise as a result of monoclonality (e.g., because of bone-
marrow transplant) and is sometimes observed in as-
sociation with MZ twinning (reviewed in Belmont
1996). Studies of artificial chimeras, combined with in-
ferences of precursor-cell population size that are based
on the frequency of X skewing within and between tis-
sues, have led to the conclusions that in mouse (1) X
inactivation has not yet occurred in the inner cell mass
of the blastocyst, (2) x10–20 embryonic precursor cells
must be present at the time that an X is designated to
be inactivated, and (3) inactivation occurs prior to the
differentiation of embryonic tissues. Therefore, X in-
activation is assumed to be initiated in the embryonic
ectoderm shortly after blastocyst implantation but may
take several days to complete (Gardner and Lyon 1971;
Nesbitt 1971; Tan et al. 1993).
Confined placental mosaicism (CPM) is detected in
∼2% of viable pregnancies ascertained through chori-
onic villus sampling (CVS) at 10–12 wk gestation (Mik-
kelsen and Ayme 1987; Ledbetter et al. 1992; Wang et
al. 1993). CPM refers to the presence of two karyotyp-
ically different cell lines (usually trisomic and diploid)
in the placenta but only one cell line (usually diploid)
in the fetus. Although many pregnancies with CPM pro-
gress to term uneventfully, some may result in sponta-
neous abortion, intrauterine growth retardation (IUGR),
or perinatal morbidity (for review, see Kalousek 1994).
Risk of abnormal outcome increases when high levels
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of trisomy persist in term placenta and depends on the
chromosome involved (Kalousek et al. 1991). CPM may
have a meiotic origin, in which a trisomic chromosome
is lost in an embryo/fetal progenitor cell of a trisomic
conceptus, or may arise from somatic duplication of one
chromosome within the placental cell lineage of a normal
diploid conceptus. Previous studies have shown that the
majority of the CPM for autosomes 9, 16, and 22 are
meiotic in origin, whereas CPM for autosomes 2, 7, 8,
10, and 12 are predominantly somatic in origin (Rob-
inson et al. 1997). Poor pregnancy outcome appears to
be restricted to CPM of meiotic origin, which is also
correlated with a high level of trisomy in the placental
tissues, compared with somatic CPM conceptions.
At the blastocyst stage of development, the majority
of cells contribute to extraembryonic lineages, whereas
only three to five cells of the inner cell mass are pro-
genitors of the embryo proper (Gardner and Lyon 1971).
Thus, the dichotomy between high levels of trisomy in
placenta and the absence of trisomic cells in the fetus
may be achieved by chance incorporation of only di-
somic cells into the few embryo/fetal progenitors, such
that only those with primarily disomic embryo precursor
cells survive (Kalousek and Dill 1983). There might also
be a mechanism to preferentially allocate aneuploid cells
to extraembryonic lineages, as occurs for polyploid cells
in mouse chimeras made with a mix of polyploid and
diploid cells (James et al. 1995; Everett and West 1996).
In either case, X inactivation would likely be random in
the embryo proper, since it is not expected to occur until
several cell divisions later, when the pool of embryo/fetal
progenitor cells has increased in size (Nesbitt 1971). Al-
ternatively, the pool of embryo/fetal progenitors in CPM
cases at the time of X inactivation may be severely re-
stricted, as a consequence of either poor early growth
or extreme selection against trisomic cells after X in-
activation has occurred. An effective reduction in em-
bryonic progenitors at the time of X inactivation should
be associated with increased incidence of nonrandom
(skewed) X inactivation.
To determine whether the effective embryo precursor
pool might be reduced in pregnancies associated with
significant placental mosaicism, X-inactivation status
was evaluated in 28 cases of CPM, 22 of which were
informative at the androgen-receptor (AR) locus. A risk
for trisomy in embryonic progenitors would be expected
to be limited to the cases showing a meiotic origin of
the trisomic cell line in the placenta, since “somatic”
CPM is thought to arise in either the trophoblast or
chorionic lineages after differentiation. Therefore X-in-
activation results were analyzed separately for CPM
cases of meiotic origin and CPM cases of somatic origin
and were compared. Uniparental disomy (UPD), the in-
heritance of the two copies of a chromosome from the
same parent, may sometimes be associated with placen-
tal mosaicism; therefore, X skewing in cases of UPD was
analyzed also.
Methods
Ascertainment of Cases and Origin of Trisomy
A description of ascertainment, cytogenetic analysis,
and DNA extraction of CPM cases has been given in a
report by Robinson et al. (1997). In brief, most preg-
nancies were ascertained through mothers undergoing
CVS for advanced maternal age and in which a trisomic
cell line was identified. In most cases the abnormal cell
line was absent from amniotic fluid and fetal blood.
However, a few cases were also included if the level of
trisomy in amniotic fluid was low (!12%) and/or no
indication of trisomy mosaicism in blood was present.
In these cases, it was assumed that the trisomy detected
in cultured amniotic fluid was due to placenta contam-
ination. Additionally, some cases in which ascertainment
initially was due to an abnormal triple-screen result, ul-
trasound abnormality (usually IUGR), maternal anxiety,
previous aneuploidy, mosaic amniocentesis, or IUGR
noted at birth were included in the study. Ascertainment
of UPD 15 is as reported previously (Robinson et al.
1993).
The origin of trisomy had been determined previously
in many of the CPM cases tested (Robinson et al. 1997).
In six cases however, no molecular data were available,
and we inferred origin in the following manner: Since
CPM for chromosomes 16 and 22 is almost always mei-
otic (Robinson et al. 1997), case 93.73, which involves
CPM 16 and a high level of trisomy in placenta samples,
and case 93.122, which involves CPM 22, were classified
as “probably meiotic.” Case 94.36 involves trisomy 8
mosaicism, which is likewise almost always somatic in
origin. CPM 2 is also generally somatic, particularly if
the level of trisomy in the placenta is low, as it was for
case 93.83. In the two remaining cases of unknown or-
igin—cases 92.77 (CPM 17) and 92.20 (CPM 20)—a
probable somatic origin was inferred on the basis of low
levels of trisomy and confinement of the trisomic lineage
to just the chorion of the placenta.
Our control adult females consisted of 11 mothers of
CPM cases, 10 mothers of UPD cases, and 7 females
who were either mothers of normal babies or random
adults. We do not know the maternal ages in many of
these cases. However, the ages of the random adults were
24–38 years, most CPM mothers ascertained in our stud-
ies were 35–45 years of age, UPD is associated with
increased maternal age, and at least one UPD mother
was 150 years of age when a blood sample was taken
for DNA analysis. Thus we estimate that most of our
controls were 30–50 years of age.
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DNA Studies
When possible, blood samples from CPM cases were
obtained from both parents, and fetal/newborn DNA
was obtained from either cord blood obtained either at
term or, in cases of fetal demise, fetal tissues. Tissue from
trisomic material was obtained from either CVS samples
or term placentas. Blood samples from UPD cases were
obtained during infancy or childhood, for the purpose
of confirmation of the clinical diagnosis of Prader-Willi
syndrome or Angelman syndrome. DNA was extracted
according to standard protocols. Both diagnosis of UPD
and DNA typing of parents and child/fetus were per-
formed by PCR amplification of highly polymorphic mi-
crosatellite markers, as described elsewhere (Robinson
et al. 1993).
AR-Gene Methylation Assay
Inactivation status of the X was assessed by methyl-
ation at the AR locus. In somatic tissues there is a strong
correlation between X inactivation and the methylation
status of the CpG islands associated with genes (re-
viewed in Gartler and Riggs 1983). Previous studies by
Allen et al. (1992) have specifically shown that meth-
ylation at the human AR locus is correlated with X in-
activation in somatic tissues. CAG repeats in the first
exon of the gene are closely linked to HpaII restriction
sites. HpaII is a methylation-sensitive enzyme that cuts
only the unmethylated (in this case, the active) X. There-
fore, amplification of HpaII-digested DNA by use of
primers that flank the CAG and HpaII site will amplify
only the copy on the inactive X. Heterozygosity at this
locus is estimated to be 90%, with 20 alleles.
One microgram of each DNA sample were digested
with 10 U HpaII in a total volume of 10 ml. For each
sample, a control with 1 mg DNA and enzyme buffer
(but no enzyme) was prepared. DNA samples from males
(usually from the father’s blood) were also digested, as
a control for complete HpaII digestion. Incubation was
performed overnight at 37C. One microliter of the di-
gested or control sample was used for amplification. Am-
plification of the control (undigested) sample was used
to determine whether preferential amplification of alleles
had occurred. PCR was performed in a total volume of
25 ml containing 200 mM dNTP, 0.005 U Taq polymer-
ase, 1.5 mM MgCl2, 2.5 ml 10 #Taq buffer, and 0.28
mM each primer. Primer sequences were as follows: for-
ward primer, 5′ GCT GTG AAG GTT GCT GTT CCT
CAT 3′; reverse primer, 5′ TCC AGA ATC TGT TCC
AGA GCG TGC 3′. PCR cycling conditions were 95C
for 3 min (initial denaturation); 95C for 45 s, 60C for
30 s, and 72C for 30 s, for 28 cycles;, and 72C for 7
min (final extension). An equal volume of urea-loading
buffer was added to the PCR products. A maximum
amount of 10 ml was loaded onto a 5% polyacrylamide/
50% urea gel and was electrophoresed for 1 h 20 min–1
h 40 min at 50 W. Bands were visualized by silver
staining.
In the male control samples, no amplification should
have occurred in the digested sample after PCR, since
males have only an active X, which therefore should be
unmethylated and sensitive to digestion by HpaII and
should elude amplification by the AR primers. There-
fore, the absence of a band on the polyacrylamide gel
after amplification of the digested male samples was
taken as an indication that complete digestion by HpaII
had occurred. However, this is only an indirect way of
ensuring complete digestion by HpaII. It should be noted
that subsequent PCR amplification of DNA that has not
been digested to completion may lead to underestima-
tion of skewing. In our study, the male control DNA
was completely digested, as judged on the basis of the
lack of any PCR product in the digested sample.
Estimation of Degree of Skewing
Polyacrylamide gels were dried between two pieces of
cellophane or on blotting paper and were scanned by
an Apple Color OneScanner Dispatcher. NIH Image, ob-
tained on-line (http://rsb.info.nih.gov/nih-image), was
used to analyze the band intensities. Degree of skewing
was defined as the band intensity of the most intense
allele, relative to the total intensity of both alleles. Back-
ground levels were taken into account by setting the peak
base to the average intensity reached on either side of
the main peaks. The areas under the peaks correspond-
ing to each band, from both a HpaII-digested sample
and an undigested sample, were determined. Values for
the digested samples were normalized with those for the
undigested samples, to account for preferential allele am-
plification. Thus, degree of skewing was calculated as
, where Bd1 represents(Bd1/Bu1)/(Bd1/Bu1 Bd2/Bu2)
the band intensity of the more intense HpaII-digested
allele, Bd2 represents the band intensity of the fainter
HpaII-digested allele, and Bu1 and Bu2 are the corre-
sponding bands from the undigested samples. Accurate
quantification of allele ratios is not really possible with-
out controlling for the facts that (a) the PCR amplifi-
cation is always in the linear range and (b) development
of gels is constant from gel to gel, with little or no back-
ground, such that there is linearity with respect to band
intensity. We found a linear correlation when we per-
formed amplification of the AR for mixtures of DNA
samples from two individuals homozygous for different
AR alleles, using ratios of DNA that were within a range
of 1:10–10:1, with our usual DNA concentrations.
However, there is uncontrollable sample-to-sample var-
iation in both amplification intensity and gel-exposure
levels. Nonetheless, there should be no bias induced from
these fluctuations, since maternal controls, meiotic
1356 Am. J. Hum. Genet. 61:1353–1361, 1997
Table 1
X Inactivation in Fetal and Extraembryonic Tissues of Meiotic and Somatic CPM
CASE
ABNORMAL
CELL LINE
ORIGIN OF
TRISOMY
FETAL TISSUE EXTRAEMBRYONIC TISSUE
Source
Degree of
Skewing
(%) Inactive Allele Source
Degree of
Skewing
(%) Inactive Allele
94.25 47,2 Meiotic, maternal Blood 100 Maternal Chorionic villi 56
91.53 47,7 Meiotic, maternal Blood 73 Not determined Amnion 54
Chorion 76
CPM16-36 47,16 Meiotic, maternal Brain 100 Maternal Amnion 58
Spleen 100 Maternal
Kidney 79 Maternal
Skin 51
94.21 47,16 Meiotic, maternal Blood 100 Paternal Chorionic villi 59
95.28 47,16 Meiotic, maternal Diaphragm 100 Paternal
91.71 47,16 Meiotic, maternal Blood 70 Paternal Amnion 52
Chorion 92 Paternal
Chorionic villi 92 Paternal
91.55 47,16 Meiotic, maternal Blood 83 Paternal Amnion 77
Chorion 60
Chorionic villi 55
93.43 47,16 Meiotic, maternal Intestine 100 Paternal
93.73 47,16 Probably meiotica Blood 100
90.9 47,16 Meiotic, maternal Blood 74
93.122 47,22 Probably meiotica Blood 76
95.66 47,22 Meiotic, maternal Blood 100 Maternal Amnion 59
Chorionic villi 86 Maternal
91.54 47,2 Somatic Blood 62
92.29 47,2 Somatic Blood 74
93.83 47,2 Probably somaticb Blood 60
92.81 47,2 Somatic Blood 73
95.21 47,3 Somatic Blood 75 Chorionic villi 68
91.85 47,8 Somatic Blood 70 Chorionic villi 89 Paternal
94.36 47,8 Probably somaticc Blood 50
93.92 47,12 Somatic Blood 51
92.77 47,17 Probably somaticb Blood 82
92.20 47,20 Probably somaticb Blood 57
a Trisomy 16 CPM or trisomy 22 CPM is usually meiotic; high levels of trisomy in these cases are consistent with this conclusion (see text).
b Cases 93.83, 92.77, and 92.20 show low levels of trisomy, confined to the chorion.
c Case shows low-level trisomy 8 mosaicism in amniotic fluid; however, mosaic trisomy 8 is usually somatic (see text).
Table 2
Extreme Skewing of X Inactivation
Sample
No. with Skewing
x90%/Total No.
Cases:
Meiotic CPM (newborn) 7/12 (58%)*
UPD (age 0–15 years) 3/11 (27%)
Controls:
Somatic CPM (newborn) 0/10
Adult femalesa 1/27 (4%)
a Mothers of CPM, UPD, and healthy newborns.
* compared with somatic CPM andP  .005 P 
compared with control adult females..0003
CPM, and somatic CPM were run side-by-side under
same conditions and on the same gels. In addition,HpaII
digestion and amplification of many samples were re-
peated on separate gels, to test for reproducibility of
digests, and reported values in such cases are the average
of two readings from two gels. It should be emphasized
that the focus of this study is on identification of ex-
tremely skewed values (i.e., close to 100% inactivation
of one allele), which should not be affected by fluctua-
tions in band quantitation, since, in these cases, there
was complete disappearance of one band after sample
digestion.
Results
In total, 28 cases of CPM were tested, 22 of which
were informative at the AR locus. Twelve informative
cases were classified as meiotic in origin, and 10 were
of probable somatic origin of the trisomic lineage. Over-
all, a higher degree of skewing was observed in the mei-
otic CPM samples than in the somatic CPM samples
(tables 1 and 2; also see fig. 1). Specifically, extreme
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Figure 1 AR methylation analysis. U  undigested; and D  digested with HpaII. a, Example of meiotic CPM cases. In the pedigree on
the left, the paternal allele is preferentially inactivated in the blood of case 93.43; X inactivation appears to be random in the mother; and
HpaII digestion is complete in the father, as indicated by a lack of product in the digested paternal sample. In the pedigree on the right, the
amnion displays random X inactivation, whereas the blood shows moderate skewing and the chorionic villi show extreme skewing with
preferential inactivation of the paternal allele. b, Extreme skewing observed in some but not all fetal tissues sampled from case CPM16-36.
Digests were repeated for verification, with the same result. c, AR methylation analysis in somatic CPM cases. Random X inactivation (e.g.,
!75% skewing) is seen in each case. d, AR methylation analysis in UPD 15 cases. Prader-Willi syndrome patients with maternal UPD 15
(UPD15-44, UPD15-293, and UPD15-169) show extremely skewed X inactivation, whereas the Angelman syndrome patient with paternal UPD
15 (UPD15-112) does not.
(190%) skewing was observed in the majority (7/12) of
the meiotic cases, but in none of the 10 somatic cases
( ) and in only 1 of 27 control females (P  .005 P 
; Fisher’s exact test). In most cases blood was used.0003
for the analysis, although other fetal tissues were used
in three of the meiotic cases. We do not know what
degree of skewing to expect in fetal tissues in humans;
however, distributions of skewing of X inactivation have
been calculated for multiple tissues in mouse and have
not been found to be significantly different from that
observed in blood (Nesbitt 1971). Exclusion of the data
from fetal tissues does not alter the finding of signifi-
cantly increased skewing in cases associated with meiotic
CPM. No preferential inactivation of the maternal allele
versus the paternal allele was observed in the skewed
cases.
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Table 3
X Inactivation in Female UPD Cases Ascertained Postnatally
Case Type (Origin) of UPD
Degree of Skewing
(%) Allele Inactivated
UPD15-2 Maternal UPD 15 (meiotic) 59 Not determined
UPD15-5 Maternal UPD 15 (meiotic) 87 Maternal
UPD15-40 Maternal UPD 15 (meiotic) 50 Not determined
UPD15-44 Maternal UPD 15 (somatic) 98 Maternal
UPD15-60 Maternal UPD 15 (somatic) 64 Not determined
UPD15-116 Maternal UPD 15 (meiotic) 76 Not determined
UPD15-169 Maternal UPD 15 (meiotic) 100 Maternal
UPD15-209 Maternal UPD 15 (meiotic) 54 Not determined
UPD15-293 Maternal UPD 15 (meiotic) 94 Paternal
UPD15-112 Paternal UPD 15 (somatic) 65 Not determined
SRS11 Maternal UPD 7 (somatic) 59 Not determined
In our control adult females consisting of mothers of
CPM, UPD, and normal births, 33% (9/27) were found
to be moderately (75%–90%) skewed; however, only
one case (a mother of a CPM 22) showed skewing 190%
(allele ratios 9:1). In a study of newborn blood, non-
random inactivation with 175% skewing (allele ratios
3:1) was observed in ∼9% of samples and 190% skew-
ing was observed in !2% of samples (Busque et al.
1996). The level of skewing in blood increases with age,
however, and extreme (190%) skewing was observed in
4.5% of women 28–32 years of age and in 23% of
women 160 years of age. In a separate study of adult
women (ages not specified), ∼20% showed 180% skew-
ing and 9% showed 190% skewing, consistent with the
results given above (Naumova et al. 1996). Our adult
control values are consistent with these published results.
Using adult women as a control group is expected to be
conservative for testing the hypothesis that there is in-
creased skewing in newborn blood of CPM cases. Ex-
traembryonic tissues, when available, were rarely
skewed, even in two cases showing 100% skewing in
fetal tissue. When examined, X inactivation in the am-
nion, which is of both embryonic and extraembryonic
origin, always appeared to be random when this test
was used.
In the present study, two of seven samples with meiotic
UPD 15 showed extreme skewing, and one showed mod-
erate skewing (table 3 and fig. 1d), consistent with the
idea that a subset of such cases may lose the paternal
chromosome postzygotically and are in fact associated
with trisomy CPM. One case of UPD 15 attributed to
somatic duplication of the maternal chromosome 15 also
showed extreme skewing. Somatic UPDs are also likely
to be associated with CPM. However, in this case the
abnormal cell line may be, for example, a monosomy
rather than a trisomy 15. One case of meiotic UPD 7,
ascertained through the presence of Russell-Silver syn-
drome, showed random X inactivation.
Discussion
X inactivation is believed to occur randomly in so-
matic tissue, and extreme skewing is expected to be rare
except in females with X rearrangements, X-linked dis-
eases, or mutations in the XIST locus. In a prospective
study of newborn blood, extreme (190%) skewing was
observed in !2% of samples (Busque et al. 1996). The
level of skewing increases with age, yet extreme skewing
was observed in only 4.5% of women 28–32 years of
age in the same study and in only 1 (4%) of the 27
women in our own study. Our observation of an ex-
tremely skewed pattern of X inactivation in 58% of fetal
tissue or newborn blood samples from CPM cases with
a meiotic origin of the trisomy deviates significantly from
these previously observed rates of extreme skewing.
Extraembryonic tissues, when available, were rarely
skewed, even in two cases showing 100% skewing in
fetal tissue, implying that a primary tendency to skewing
(i.e., skewing due to a mutation in the XIST gene) is
unlikely in these cases. It should be noted, however, that
the reliability of the AR-methylation assay for X inac-
tivation has not been thoroughly examined in extraem-
bryonic tissues, and, therefore, the results for these sam-
ples must be interpreted with caution. A result suggestive
of nonrandom X inactivation was observed in some sam-
ples of chorion (villus stroma or chorionic plate), in-
cluding one case showing a tendency to inactivate the
maternal allele. Although there is evidence for prefer-
ential inactivation of the paternal X in human tropho-
blast, studies of inactivation in chorion generally show
random inactivation (Migeon et al. 1985; Harrison
1989; Mohandas et al. 1989; Goto et al. 1992). In ad-
dition, studies of the distribution of trisomic cells in the
placenta of CPM cases show large site-to-site variation
in the distribution of trisomic cells, indicating that the
development of the placenta is quite clonal (Henderson
et al. 1996). This clonality could be reflected by skewed
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X inactivation in individual placental biopsies and may
depend on the size or location of the sample taken. Fur-
ther studies of CPM and normal placentas, taking bi-
opsies in a controlled manner, are therefore necessary to
determine whether X inactivation is altered in any way
in placentas of CPM cases.
Some cases of UPD have been ascertained subsequent
to the finding of CPM for the involved chromosome and
are inferred to arise from “rescue” of a trisomic zygote
through somatic chromosome loss (Cassidy et al. 1992;
Purvis-Smith et al. 1992; Kalousek et al. 1993). How-
ever, diagnosis of UPD 15, associated with Prader-Willi
and Angelman syndromes, is normally made postnatally,
and it is not known what proportion might be associated
with CPM. Given the high rate of aneuploidy in human
gametes, it is also possible that the majority of maternal
UPD 15 results from a fertilization of a disomy 15 oocyte
with a nullisomy 15 sperm (for discussion, see Robinson
et al. 1991). In the present study, 3 of 10 samples with
UPD 15 showed extreme skewing, which would be con-
sistent with a proportion of UPD arising in association
with CPM and would suggest that X-linked recessive
disease may be more common in such patients.
Several explanations may be proposed to explain the
occurrence of a skewed pattern of X inactivation in em-
bryonic tissues of meiotic CPM cases. First, it is possible
that designation of an X to be inactivated occurs prior
to (or at the time of) the trisomic rescue event. All sub-
sequent cells derived from the disomic cell would then
be expected to have the same X inactivated; hence one
would expect to see 100% skewing of X inactivation in
the derivative cell line. Although this is an attractive
hypothesis, it is unlikely that X inactivation could occur
prior to the event generating the mosaicism. If it is as-
sumed that the somatic loss occurred only once, then it
must have occurred prior to the differentiation of cho-
rion from embryonic progenitors in the inner cell mass
of the early blastocyst, since both chorion and embryo
typically show disomic cells. Although results of one
study suggest that the X-counting mechanism may pos-
sibly occur at the morula stage, well before the process
of X inactivation itself (Migeon et al. 1996), the actual
commitment of a particular X to be inactivated must
occur at a later stage of development (Gardner and Lyon
1971; also see Brown and Robinson 1997). It is believed
that only three to five cells of the developing blastocyst
actually contribute to the resulting fetus (Gardner and
Lyon 1971), and the level of skewing in the normal fe-
male population would be expected to be much greater
if X inactivation were to occur at or before this stage
of development. Furthermore, in case CPM16-36, ex-
treme skewing was observed in some but not all tissues
(fig. 1b) implying that more than one disomic cell was
present when X inactivation occurred.
It is more probable that X inactivation occurs multiple
cell divisions after the trisomic rescue. To explain the
observed skewing in meiotic CPM cases, we therefore
assume a reduction, at the time of X inactivation, in the
number of cells present that will ultimately contribute
to the fetus. A reduction in the total number of cells at
the time of X inactivation has been proposed as an ex-
planation for increased X skewing in some female MZ
twins (Goodship et al. 1996). It has been hypothesized
that onset of tissue differentiation in MZ twins might
be dependent on the time since fertilization, rather than
on the cell mass. If this hypothesis is true, poor early
growth up to the blastocyst stage may similarly result
in reduced cell mass at the time of X inactivation in
CPM cases. In addition, it has been hypothesized that
twinning may be caused by mosaicism for a genetic ab-
normality (Hall 1996) and that CPM may result from
a twinning event caused by repulsion of the trisomic
from disomic cells, with subsequent death/resorption of
the trisomic twin (Kalousek 1993).
It should be noted, however, that the frequency of
skewing in MZ twins has been estimated to be 18%
(Goodship et al. 1996), which is lower than that ob-
served in the CPM cases in the present study. Another
possible factor that may contribute to skewing in CPM
cases would occur if the majority of embryo progenitors
were trisomic but selection against these cells early in
development resulted in only one or a few disomic cells
actually contributing to the resulting embryo/fetus. This
hypothesis does not require a reduction in the total num-
ber of cells present at the time of differentiation. Con-
sistent with the hypothesis that selection and high cell
death rate in the pool of fetal precursor cells can occur
early in development is the extremely skewed X-inacti-
vation seen in X-autosome translocations, which is at-
tributed to severe selection against cells that inactivate
the translocated X (Zabel et al. 1978).
Interestingly, a reduction in embryo-precursor pool
size can also be induced by maternal administration of
mitomycin-C in the mouse (Tam and Snow 1981; Snow
1985). The embryos exhibit catch-up growth and are of
normal size, despite early growth delay. In these mice,
various abnormalities were seen, which were attributed
to the higher than usual rate of cell division during the
catch-up phase. There seemed to be especially poor de-
velopment of germ cells. CPM has been identified only
since 1983, and thus fertility of identified cases is un-
known; however, if X-inactivation skewing is a sign of
small embryo-precursor size, skewed cases may also be
at increased risk of fertility problems. Also, a recent
study has suggested that, even if development of the
germ cells is not impaired by early growth problems,
reduction in fertility could occur, since germ-cell aneu-
ploidy may be present in some CPM cases (Stavropoulos
1997).
It should be emphasized that CPM may arise through
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multiple mechanisms and that a reduction in embryo-
precursor size may be common only for certain trisomies
(e.g., 16 and 22). Among CPM cases, chromosome-spe-
cific differences are seen in the distribution of trisomic
cells within the placenta (i.e., trisomy either confined to
trophoblast or chorion or present in both) (Godsen et
al. 1995) and in the relative frequency of meiotic versus
somatic origin of the trisomy (Robinson et al. 1997).
One would expect that differential chromosome involve-
ment in CPM could be also influenced by the efficiency
with which any potential selection against specific tri-
somies occurs in embryonic lineages. Depending on the
involved chromosome, some trisomies have been shown
to be poorly tolerated in some mouse somatic tissues
(Gropp et al. 1983). Conversely, in mouse chimeras ar-
tificially constructed by use of trisomy 16 and normal
disomic blastocysts, viability was reduced when the kar-
yotype of placenta and fetal cells differed compared with
that of chimeras with fully trisomic placenta and fetus,
indicating that, for some chromosomes, a dichotomy
between placental and fetal karyotype may not be well
tolerated, thereby resulting in selection against CPM
(Bogart and Miyabara 1990). For human trisomy 13
and trisomy 18, it has been shown that survival to term
is not possible unless the trisomy is lost from placental
trophoblast (Harrison et al. 1993), indicating that, for
these chromosomes, it may be the placenta and not the
developing embryo/fetus itself that does not tolerate the
trisomy. Unfortunately, data on humans suffer from so
much ascertainment bias that the relative frequency with
which CPM for any particular chromosome occurs, rel-
ative to its frequency in generalized mosaicism, cannot
be accurately calculated, and it is difficult to predict how
selection might act on different mosaic trisomies during
embryonic development.
In summary, a high rate of a skewed pattern of X
inactivation has been observed in cases of meiotic CPM.
It is hypothesized that this results from a reduction in
the effective embryonic-progenitor cell pool, because of
poor growth and/or selection against trisomic cells in
early embryogenesis. Consequently, abnormal preg-
nancy outcomes associated with CPM may be due, in
part, to either a high rate of cell death in early embryonic
development or, potentially, to a rapid catch-up growth
phase. Furthermore, the results of the present study
would predict that X-linked diseases should occur at
increased frequency in female pregnancies associated
with CPM or UPD. The true population incidence of
CPM is unknown and could be either (a) higher than
the 2% ascertained through CVS, because of incomplete
detection, or (b) lower than that frequency, because CVS
samples are biased by increased maternal age. None-
theless, since only 2% of female newborns show extreme
skewing of the X, CPM is likely a major factor con-
tributing to skewed X inactivation in the newborn
population.
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